Biomedical Applications of Nanoscale Devices

SUMMARY

REASON FOR STUDY AND ITS IMPORTANCE

This study was begun in order to help define the field of nanobiotechnology and its utility in creating devices of enhanced sensitivity or function that are useful in biomedical research, drug discovery and clinical therapy. Nanotechnology, a buzzword since the 1980s, is now coming of age. Discoveries and inventions are building on one another in ways that can scarcely be anticipated. As future-guru Ray Kurzweil is fond of pointing out, technology advances in an exponential fashion. Nanotechnology is now approaching the steep part of the curve. At the same time, it is being combined with a relatively mature biotechnology. The result is a cornucopia of new ideas, inventions and commercial products.

With this report, we hope to identify companies and products in this emerging field, and to sort out those with bright prospects from the not-so-likely contenders. We feel that this will be a valuable contribution to all those with an interest in biomedical devices.

INTENDED AUDIENCE OF THIS REPORT

This report is intended for entrepreneurs, venture capitalists, CEOs, business and product development officers, R&D directors, intellectual property lawyers and research scientists and bioengineers looking for an overview of biomedical applications of nanotechnology and the potential for commercialization of this technology.

SCOPE AND CONTENT OF THE REPORT

This report covers biomedical nanoscale devices, i.e. any biomedical contrivance in which a critical component is measured in nanometers (nm). One generally accepted definition of nanotechnology is that it involves engineering objects with dimensions of less than 100 nm. In this report, we are somewhat more liberal. We take it as given, for instance that microelectromechanical systems (MEMS) are evolving into nanoelectromechanical systems (NEMS), even as microfluidics are already advancing to nanofluidics.

Biomolecules all have dimensions in the nanometer range, but there is nothing to be gained by re-classifying all of biotechnology as nanotechnology. Only when biomolecules are combined with manufactured nanoscale items or are significantly re-engineered are they considered in this report. Likewise, some semiconductor chips now have features with dimensions smaller than 90 nm but it does no good to consider the entire semiconductor industry under the heading "nanotechnology." We do not discuss general-purpose semiconductor chips here, even when incorporated into a medical device.

Devices that are covered in this report include things such as: bioassays that use nanoscale components, including thin films and nanoparticles; nanotools that are applied to life science research including atomic force microscopes and accessories; drugs and drug delivery systems that use nanoscale capsules, fullerenes or MEMS; fullerene objects, such as nanotubes, as applied to medical devices; and quantum dots as applied to bioanalytical systems. Also covered, in a prospective sense, are artificial cells, artificial organs and artificial organisms.

METHODOLOGY AND INFORMATION SOURCES

The information reported herein has been gathered from a variety of industry and other sources. The 10K forms and other SEC filings from public companies have been examined along with annual reports, catalogues, press releases et cetera. The World Wide Web is a rich source of information, as almost every commercial concern now has its own web page. Product literature and trade journals have been monitored, including BCC's own Nano/Bio Convergence News and proceedings of BCC Conferences, including the Nanoparticles Conference-2002 and Nanotech and Biotech Convergence-2002, for which the author of this report is program chairman. Where appropriate, medical literature and scientific literature have served as a research source.

We have also gathered information from the U.S. government, the European Commission and private foundations and organizations, including the Rand Corporation and the Institute of Nanotechnology.

Armed with the industry and statistical information garnered above, market participants have been interviewed to fill gaps in understanding.

TABLE OF CONTENTS

INTRODUCTION

• REASON FOR STUDY AND ITS IMPORTANCE
• INTENDED AUDIENCE OF THIS REPORT
• SCOPE AND CONTENT OF THE REPORT
• METHODOLOGY AND INFORMATION SOURCES
• ANALYST'S CREDENTIALS
• RELEVANT BCC REPORTS
• MONTHLY NEWSLETTERS
• BCC ON-LINE SERVICES

SUMMARY

• Summary Table:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Summary Figure:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)

OVERVIEW

• COVERAGE DEFINED
  • COVERAGE DEFINED (CONTINUED)
• NANOMEDICINE
• Table 1 NANOMEDICINE TAXONOMY
  • NANOTECHNOLOGY
    • Nanotechnology (Continued)
• Table 2 SIZES OF NANOSCALE OBJECTS-NATURE VS. MANUFACTURE
  • BIOTECHNOLOGY VS. NANOTECHNOLOGY
    • Biotechnology vs. Nanotechnology (Continued)
    • Biotechnology vs. Nanotechnology (Continued)
  • LITHOGRAPHY
  • OBSTACLES TO THE DEVELOPMENT OF NANOTECHNOLOGY
    • FEAR OF NANO
      • Fear of Nano (Continued)
      • Fear of Nano (Continued)
    • SHORTAGE OF EXPERTS
    • HYPE
      • HYPE (Continued)

REGULATION

• REGULATION OF DRUGS AND BIOMEDICAL DEVICES
  • REGULATION IN THE U.S.
    • Devices
      • Devices (Continued)
• Table 3 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN MEDICAL DEVICE REGULATION
  • Devices (Continued)
  • Drugs and Biologicals
• Table 4 STAGES OF DRUG CANDIDATE REVIEW
  • Diagnostics
  • Orphan Product Status
  • INTERNATIONAL ISSUES
    • ISO 9000
  • GENERAL REGULATION OF NANOTECHNOLOGY
    • GENERAL REGULATION OF NANOTECHNOLOGY (CONTINUED)

TYPICAL NANOSCALE DEVICES

• CONCEPTS AND REALITIES
  • THE ASSEMBLER
    • The Assembler (Continued)
    • The Assembler (Continued)
  • DENDRIMERS
  • ARTIFICIAL ANTIBODIES-APTAMERS
  • LIQUID CRYSTAL
  • DESIGNER MACROMOLECULES
  • PROTEINS WITH NON-NATURAL AMINO ACIDS
  • SELF-ASSEMBLING NANOSTRUCTURES
  • PORPHYRIN POLYMERS
  • BUILDING WITH VIRUSES
  • MODIFIED SPIDER SILK
  • RIBOZYMES
  • MEMS/NEMS
    • Mems/Nems (Continued)
  • MOLECULAR MOTORS
  • SPECIAL PURPOSE MOTORS
  • NANOTUBES
  • FLUORESCENCE
  • NANOTUBE THERMOMETER
    • Spiral-Shaped Nanotubes from Organic Chemicals
    • Thin Films

APPLICATIONS FOR NANOSCALE DEVICES

• Table 5 NANOSCALE DEVICES AND APLICATIONS
• Table 6 BIOMEDICAL MARKETS POTENTIALLY ADDRESSABLE BY NANODEVICES, 2002
• Table 7 GLOBAL PROJECTED SALES OF BIOMEDICAL NANOSCALE DEVICES BY APPLICATION, THROUGH 2007 ($ MILLIONS)
  • ARTIFICIAL CELLS
    • ARTIFICIAL CELLS (CONTINUED)
    • ARTIFICIAL CELLS (CONTINUED)
    • MARKET OPPORTUNITY FOR ARTIFICIAL CELLS
• Table 8 GLOBAL BIOMEDICAL MARKET REVENUES FROM ARTIFICIAL CELLS, THROUGH 2007 ($ MILLIONS)
  • ARTIFICIAL ORGAN IMPLANTS
    • AUDITORY BRAINSTEM IMPLANT
    • ARTIFICIAL RETINA
      • Artificial Retina (Continued)
    • ARTIFICIAL PANCREAS
    • MARKET OPPORTUNITY FOR ARTIFICIAL ORGANS
• Table 9 GLOBAL REVENUES DERIVED FROM NANOSCALE ARTIFICIAL ORGANS, THROUGH 2007 ($ MILLIONS)
  • BIOTAGS
• Table 10 PROPERTIES OF SELECTED BIOTAGS
  • DIAGNOSTICS AND ANALYTICS
• Table 11 MEDICAL ANALYSIS AT DIFFERENT LEVELS OF RESOLUTION
• Table 12 COMMONLY USED TOOLS FOR BIOMOLECULAR ANALYSIS
  • BIOSENSORS
• Table 13 BIOSENSOR COMPONENTS
• Table 13 (CONTINUED)
  • Biosensors (Continued)
• Table 14 BIOASSAYS EMPLOYING NANSCALE COMPONENTS
  • RESONANCE LIGHT SCATTERING
  • SURFACE PLASMON RESONANCE
  • THIN FILM PLANAR WAVE-GUIDE TECHNOLOGY
  • OLFACTORY RECEPTOR SENSORS-THE ARTIFICIAL NOSE
    • Olfactory Receptor Sensors-The Artificial·Continued)
  • CANTILEVERS
  • NANOPARTICLE-BASED ASSAYS
    • Nanoparticle-Based Assays (Continued)
    • Nanoparticle-Based Assays (Continued)
  • MAGNETIC RESISTANCE ASSAYS
  • MEMBRANES
  • PIEZOELECTRIC ACOUSTIC ASSAYS
  • MICRO/NANO TRANSPONDERS
  • LIVING CELL BIOSENSORS
  • NANOCRYSTAL ANTENNA TRANSDUCER
  • PROTEIN BENDING BIOSWITCHES
  • ELECTRICAL FLOW THROUGH DNA
  • POROUS GLASS SENSORS
  • MICRO- AND NANOFLUIDICS
    • Micro- and Nanofluidics (Continued)
  • QUANTUM DOTS
  • NANOARRAYS
  • MARKET OPPORTUNITY FOR DIAGNOSTICS AND ANALYTICS
    • Market Opportunity forAnalytics·Continued)
• Table 15 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Figure 1 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)
  • DRUGS AND DRUG DELIVERY
• Table 16 NANOSCALE DEVICES USED FOR DRUG DELIVERY
• Table 16 (CONTINUED)
  • FULLERENES
  • "HOMING" QUANTUM DOTS
  • NANOCLINIC
  • MOLECULAR TRANSPORT
  • IMPLANTABLE CHIPS
  • NANOPARTICLES
    • Nanoparticles (Continued)
    • Nanoparticles (Continued)
    • Nanoparticles (Continued)
    • Nanoparticles (Continued)
  • INTRACELLULAR DELIVERY REGULATION
  • LIPOSOMES AND OTHER VESICLES
    • Liposomes and Other Vesicles (Continued)
    • Liposomes and Other Vesicles (Continued)
  • NANOEMULSIONS
  • NANOSHELLS
  • PUMPS
  • ANTIVIRAL GEL
  • MARKET OPPORTUNITY FOR DRUGS AND DRUG DELIVERY
• Table 17 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, THROUGH 2007 ($ MILLIONS)
• Figure 2 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, 2002-2007 ($ MILLIONS)
  • IMAGING AND NANOTOOLS
    • ATOMIC FORCE AND SCANNING TUNNELING MICROSCOPES
      • Atomic Force and Scanning Tunneling·Continued)
    • ANGSTROVISION
    • NANOMANIPULATORS
    • X-RAY TUBES
      • X-Ray Tubes (Continued)
    • IMAGING FROM INSIDE THE BODY
    • CONTRAST AGENTS
      • Contrast Agents (Continued)
    • MARKET OPPORTUNITIES FOR IMAGING AND NANOTOOLS
      • AFM, STM and Accessories
      • X-ray Cathodes
      • Contrast Agents
• Table 18 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, THROUGH 2007 ($ MILLIONS)
• Figure 3 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, 2002-2007 ($ MILLIONS)
  • MOLECULAR MODELING
    • MOLECULAR MODELING (CONTINUED)
• Table 19 PROPERTIES SUSCEPTIBLE TO MODELING
  • MARKET OPPORTUNITY FOR MOLECULAR MODELING SOFTWARE
• Table 20 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, THROUGH 2007 ($ MILLIONS)
• Figure 4 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, 2001-2007 ($ MILLIONS)
  • BRAIN/MACHINE INTERFACE
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • BRAIN/MACHINE INTERFACE (CONTINUED)
    • WIRELESS INTEGRATED MICROSYSTEMS (WIMS)
    • IMPLANT SURFACE
    • COMMERCIAL OPPORTUNITIES FOR BRAIN/MACHINE INTERFACE
• Table 21 GLOBAL REVENUES DERIVED FROM THE BRAIN MACHINE INTERFACE, THROUGH 2007 ($ MILLIONS)

PRODUCTS-NANOSCALE DEVICES AND TOOLS

• ARTIFICIAL ORGANS
  • ARTIFICIAL RETINA-OPTOBIONICS ASR MICROCHIP
  • BIOTAGS
    • Evident Technologies-Evidots (Nanocrystals)
    • Nanoprobe-Nanogold Labels
    • Quantum Dot Corp.-Streptavidin Conjugated Qdots
• DIAGNOSTICS AND ANALYTICS
  • AMBRI SENSIDX SYSTEM
  • BIACORE SYSTEMS (SURFACE PLASMON RESONANCE (SPR))
  • BIOFORCE NANOSCIENCES-NANOPRO
  • EVIDENT TECHNOLOGIES-EVIARRAY (BIOTHREAT DETECTION SYSTEM)
  • GENICON SCIENCE-MICROARRAY TOOLKITS
  • NANOSPHERE-NANOPARTICLE PROBE ASSAYS
  • PHARMASEQ-TSUNAMI II FLOW READER AND ASSAY KITS
  • ZEPTOSEN AG-SENSICHIP PRODUCTS
  • ZEPTOMARK HIGH PERFORMANCE PROTEIN MICROARRAYS
  • DIP-PEN NANOLITHOGRAPHY-NANOINK'S NSCRIPTOR
• DRUGS AND DRUG DELIVERY SYSTEMS
  • ABI-007
  • ACTICOAT (NUCRYST PHARMACEUTICALS)
  • NANOGATE
  • P80DOX-NP
  • RENAZORB
• FLUIDICS
  • FLUIDIGM TOPAZ PROTEIN CRYSTALIZATION SYSTEM
• NANOTOOLS
  • 3RD-TECH NANOMANIPULATOR
  • ASYLUM RESEARCH-NANOFLOW FLUID CONTROLLER
  • ASYLUM RESEARCH-MOLECULAR FORCE PROBE
  • THE BIORYX 200 SYSTEM
  • HYSITRON-TRIBOINDENTER
    • Hysitron-Triboindenter (Continued)
  • JPK INSTRUMENTS NANOWIZARD ATOMIC FORCE MICROSCOPE
  • MOLECULAR IMAGING-PICO-SPM II SCANNING MICROSCOPE
  • VEECO (DIGITAL IMAGING)-BIOSCOPE ATOMIC FORCE MICROSCOPE
  • VEECO-DIMENSION 3100 SCANNING PROBE MICROSCOPE
  • VEECO-MULTIMODE PICOFORCE SYSTEM
  • VEECO-SCENTRIS CANTILEVER SENSOR RESEARCH TOOL
  • ZYVEX-S100 NANOMANIPULATOR
• MOLECULAR MODELING SOFTWARE
  • ACCELRYS-MATERIALS STUDIO 2.2
  • TRIPOS-MOLECULAR MODELING SOFTWARE
    • Tripos-Molecular Modeling Software (Continued)

FUTURE PROSPECTS

• CONVERGING DISCIPLINES
  • CONVERGING DISCIPLINES (CONTINUED)
  • CONVERGING DISCIPLINES (CONTINUED)
  • CONVERGING DISCIPLINES (CONTINUED)
• STATE OF THE INDUSTRY
• Table 22 SKILLS AND WORK STYLES OF ACADEMICS VS. INDUSTRY
  • DIVISIONS OF LABOR
    • IMAGING AND NANOTOOLS
• Table 23 COMPANIES INVOLVED IN IMAGING AND NANOTOOLS
• Table 23 (CONTINUED)
  • DRUGS AND DRUG DELIVERY
• Table 24 DRUGS OR DRUG DELIVERY
• Table 24 (CONTINUED)
  • DIAGNOSTICS AND ANALYTICS
• Table 25 COMPANIES THAT MAKE MOLECULAR DIAGNOSTICS OR ANALYTICS
• Table 25 (CONTINUED)
  • MOLECULAR MODELING
• Table 26 COMPANIES SELLING SOFTWARE FOR MODELING MOLECULES OR NANOSCALE MATERIALS
  • GENERIC NANOMATERIALS FOR MEDICAL DEVICES
• Table 27 COMPANIES THAT MAKE NANOMATERIALS FOR MEDICAL DEVICES
  • GENERAL NANOBIOTECHNOLOGY
• Table 28 GENERAL NANOBIOTECHNOLOGY (UNCLASSIFIABLE) COMPANIES
• Table 29 DISTRIBUTION OF PUBLIC VS PRIVATE NANOBIOTECH COMPANIES
• Figure 5 DISTRIBUTION NANOBIOTECH COMPANIES BY TECHNOLOGY CATEGORY (%)
  • MARKET LEADERS
• Table 30 REVENUES AND MARKET SHARE OF LEADING BIOMEDICAL NANOSCALE DEVICE COMPANIES, THROUGH 2007

COMPANY PROFILES

• 3RD TECH, INC.
  • OFFICERS:
• 454 CORP.
  • OFFICERS:
• ACCELRYS INC.
  • OFFICERS:
• ADVECTUS INTERNATIONAL, LLC
  • OFFICERS:
• AGAVE BIOSYSTEMS
  • OFFICERS:
• AKUBIO
  • OFFICERS:
• ALLEGRO TECHNOLOGIES, LTD.
  • OFFICERS:
• ALTAIR NANOTECHNOLOGIES
  • OFFICERS:
• AMBRI, LTD.
  • OFFICERS
• AMERICAN PHARMACEUTICAL PARTNERS
  • OFFICERS
• ANOSYS, INC.
  • OFFICERS:
• ARDESTA
  • OFFICERS:
• APEX NANOTECHNOLOGIES
  • OFFICERS:
• APPLIED NANOTECH, INC
  • OFFICERS: (S.I. DIAMOND)
• APPLIED NANOTECHNOLOGIES, INC.
  • OFFICERS:
• ARGONIDE NANOMATERIALS CORP
  • OFFICERS:
• ARRYX
  • OFFICERS:
• ASYLUM RESEARCH, INC.
  • OFFICERS:
• BAXTER HEALTHCARE
  • OFFICERS:
• BIACORE
  • OFFICERS:
• BIODELIVERY SCIENCES INTERNATIONAL
  • OFFICERS:
• BIOELECTROSPEC
  • OFFICERS:
• BIOFORCE NANOSCIENCES
  • OFFICERS:
• BIOPHAN TECHNOLOGIES, INC.
  • OFFICERS:
• BIOSANTE PHARMACEUTICALS
  • OFFICERS:
• BIOTROVE, INC.
  • OFFICERS:
• CALIBRANT BIOSYSTEMS
  • OFFICERS:
• CANTION A/S
  • OFFICERS:
• CAPSULUTION NANOSCIENCE AG
  • OFFICERS:
• CHIPRX, INC.
  • OFFICERS:
• C SIXTY, INC.
  • OFFICERS:
• DENDRITIC NANOTECHNOLOGIES
  • OFFICERS:
• EAGLE RESEARCH AND DEVELOPMENT
  • OFFICERS:
• EIFFEL TECHNOLOGIES LMT
  • OFFICERS:
• ELAN
  • OFFICERS:
• ENGENEOS
  • OFFICERS:
• E-SPIN
  • OFFICERS:
• EVIDENT TECHNOLOGIES
  • OFFICERS:
• FLUIDIGM
  • OFFICERS:
• GENEFLUIDICS
  • OFFICERS:
• GENERAL NANOTECHNOLOGY, INC.
  • OFFICERS:
• GENICON SCIENCES
  • OFFICERS:
• GENEOHM SCIENCES, INC.
  • OFFICERS:
• HANDYLAB
  • OFFICERS:
• HEMOTEQ NANOCOATING DESIGN
  • OFFICERS:
• HYBRID PLASTICS
  • OFFICERS:
• HYSITRON
  • OFFICERS:
• IATROQUEST
  • OFFICERS:
• IMEDD INC.
  • OFFICERS:
• INTEL
  • OFFICERS:
• INTERNATIONAL BUSINESS MACHINES (IBM)
  • OFFICERS:
• INSERT THERAPEUTICS, INC.
  • OFFICERS:
• INTEGRATED NANOSYSTEMS, INC.
  • OFFICERS:
• ISSYS (INTEGRATED SENSING SYSTEMS)
  • OFFICERS:
• JPK INSTRUMENTS AG
  • OFFICERS:
• KEREOS
  • OFFICERS:
• KLEINDIEK NANOTECHNIK
  • OFFICERS:
• KLOCKE NANOTECHNIK
  • OFFICERS:
• LIFESENSORS, INC.
  • OFFICERS:
• LIPLASOME PHARMA A/S
  • OFFICERS:
• LUNA NANOMATERIALS
• MAXWELL SENSORS
  • OFFICERS:
• MEDITECH FEFER, INC.
  • OFFICERS:
• MEMGEN, INC.
  • OFFICERS:
• MICROCHIPS, INC.
  • OFFICERS:
• MICROMOD PARTIKELTECHNOLOGIE GMBH
• MOLECULAR IMAGING CORP.
• MOLECULAR NANOSYSTEMS
  • OFFICERS:
• NANOBACLABS, INC.
  • OFFICERS:
• NANOBIO CORP.
  • OFFICERS:
• NANOBIODYNAMICS
  • OFFICERS:
• NANOBIOMAGNETICS, INC.
  • OFFICERS:
• NANOCARRIER
  • OFFICERS:
• NANOFRAMES
  • OFFICERS:
• NANOGEN
  • OFFICERS:
• NANOINK, INC.
  • OFFICERS
• NANOLYTICS
  • OFFICERS:
• NANOMED PHARMACEUTICALS
  • OFFICERS:
• NANOMEDX GMBH
  • OFFICERS:
• NANOPHARM AG
  • OFFICERS:
• NANOPLEX TECHNOLOGIES, INC.
  • OFFICERS:
• NANOPROBES, INC.
  • OFFICERS:
• NANOSENSORS GMBH
  • OFFICERS:
• NANOSPECTRA BIOSCIENCES
  • OFFICERS:
• NANOSPHERE, INC.
  • OFFICERS:
• NANOSYS INC.
  • OFFICERS:
• NANOTYPE GMBH
  • OFFICERS:
• NASCACELL GMBH
  • OFFICERS:
• NOMADICS LIFE SCIENCES
  • OFFICERS: (NOMADICS, INC.)
• NOVAVAX, INC
  • OFFICERS:
• NTERA LTD
  • OFFICERS:
• NUCRYST PHARMACEUTICALS
  • OFFICERS:
• OPTOBIONICS CORP.
  • OFFICERS:
• OXFORD BIOSENSORS LTD.
  • OFFICERS:
• PHARMASEQ
  • OFFICERS:
• PICOLITER
  • OFFICERS:
• PLATYPUS TECHNOLOGIES
  • OFFICERS:
• PROTIVERIS TECHNOLOGIES
  • OFFICERS:
• PSIVIDA
  • OFFICERS:
• QUANTUM DOT
  • OFFICERS:
• QUANTUM LOGIC
  • OFFICERS:
• QUANTUM PRECISION INSTRUMENTS PTY. LTD.
  • OFFICERS:
• SKYE PHARMACEUTICALS, INC
  • OFFICERS:
• SOLEXA LTD
  • OFFICERS:
• SPHERICS
  • OFFICERS:
• STARPHARMA GROUP
  • OFFICERS:
• SUNYX SURFACE TECHNOLOGIES GMBH
  • OFFICERS:
• SURROMED
  • OFFICERS:
• TARGESOME
  • OFFICERS:
• TDA RESEARCH
  • OFFICERS:
• THALES NANOTECHNOLOGY
  • OFFICERS:
• TRITON BIOSYSTEMS
  • OFFICERS:
• U.S. GENOMICS
  • OFFICERS:
• VEECO INSTRUMENTS INC
  • OFFICERS:
• VIALOGY CORP.
  • OFFICERS:
• XETAL BIOTECHNIKS, LTD
  • OFFICERS:
• ZEPTOSENS AG
  • OFFICERS:
• ZYVEX
  • OFFICERS:

APPENDIX

• ACRONYMS

LIST OF TABLES

• Summary Table:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Table 1 NANOMEDICINE TAXONOMY
• Table 2 SIZES OF NANOSCALE OBJECTS-NATURE VS. MANUFACTURE
• Table 3 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN MEDICAL DEVICE REGULATION
• Table 4 STAGES OF DRUG CANDIDATE REVIEW
• Table 5 NANOSCALE DEVICES AND APLICATIONS
• Table 6 BIOMEDICAL MARKETS POTENTIALLY ADDRESSABLE BY NANODEVICES, 2002
• Table 7 GLOBAL PROJECTED SALES OF BIOMEDICAL NANOSCALE DEVICES BY APPLICATION, THROUGH 2007 ($ MILLIONS)
• Table 8 GLOBAL BIOMEDICAL MARKET REVENUES FROM ARTIFICIAL CELLS, THROUGH 2007 ($ MILLIONS)
• Table 9 GLOBAL REVENUES DERIVED FROM NANOSCALE ARTIFICIAL ORGANS, THROUGH 2007 ($ MILLIONS)
• Table 10 PROPERTIES OF SELECTED BIOTAGS
• Table 11 MEDICAL ANALYSIS AT DIFFERENT LEVELS OF RESOLUTION
• Table 12 COMMONLY USED TOOLS FOR BIOMOLECULAR ANALYSIS
• Table 13 BIOSENSOR COMPONENTS
• Table 14 BIOASSAYS EMPLOYING NANSCALE COMPONENTS
• Table 15 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, THROUGH 2007 ($ MILLIONS)
• Table 16 NANOSCALE DEVICES USED FOR DRUG DELIVERY
• Table 17 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, THROUGH 2007 ($ MILLIONS)
• Table 18 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, THROUGH 2007 ($ MILLIONS)
• Table 19 PROPERTIES SUSCEPTIBLE TO MODELING
• Table 20 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, THROUGH 2007 ($ MILLIONS)
• Table 21 GLOBAL REVENUES DERIVED FROM THE BRAIN MACHINE INTERFACE, THROUGH 2007 ($ MILLIONS)
• Table 22 SKILLS AND WORK STYLES OF ACADEMICS VS. INDUSTRY
• Table 23 COMPANIES INVOLVED IN IMAGING AND NANOTOOLS
• Table 24 DRUGS OR DRUG DELIVERY
• Table 25 COMPANIES THAT MAKE MOLECULAR DIAGNOSTICS OR ANALYTICS
• Table 26 COMPANIES SELLING SOFTWARE FOR MODELING MOLECULES OR NANOSCALE MATERIALS
• Table 27 COMPANIES THAT MAKE NANOMATERIALS FOR MEDICAL DEVICES
• Table 28 GENERAL NANOBIOTECHNOLOGY (UNCLASSIFIABLE) COMPANIES
• Table 29 DISTRIBUTION OF PUBLIC VS PRIVATE NANOBIOTECH COMPANIES
• Table 30 REVENUES AND MARKET SHARE OF LEADING BIOMEDICAL NANOSCALE DEVICE COMPANIES, THROUGH 2007  

LIST OF FIGURES

• Summary Figure:
  GLOBAL MARKET FOR BIOMEDICAL NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)
• Figure 1 GLOBAL REVENUES FOR DIAGNOSTICS AND ANALYTICS EMPLOYING NANOSCALE DEVICES, 2002-2007 ($ MILLIONS)
• Figure 2 GLOBAL REVENUES FOR DRUGS AND DRUGS DELIVERY, 2002-2007 ($ MILLIONS)
• Figure 3 GLOBAL PROJECTED REVENUES FROM IMAGING AND NANOTOOLS, 2002-2007 ($ MILLIONS)
• Figure 4 GLOBAL PROJECTED REVENUES FROM MOLECULAR MODELING, 2001-2007 ($ MILLIONS)
• Figure 5 DISTRIBUTION NANOBIOTECH COMPANIES BY TECHNOLOGY CATEGORY (%)